-- 据周三提交给澳大利亚证券交易所的文件显示，Racura Oncology（ASX：RAC）和伍伦贡大学已获得新南威尔士州政府“科技券”（TechVouchers）计划的资助，用于研究(E,E)-比蒽醌对某些类型乳腺癌和卵巢癌的疗效。 文件显示，Racura与伍伦贡大学的合作旨在为RC220作为一种新型靶向疗法的开发提供临床前证据。 该合作项目的研究结果预计将在未来12个月内公布。 Racura Oncology的股价在周三的交易中上涨了2%。
Related Articles
Asia
PCL Technologies Incurs NT$94 Million Loss in Q1
PCL Technologies (TPE:4977) posted a loss attributable to owners of NT$94.1 million, or NT$1.18 per basic share, for the first quarter, according to a Tuesday Taiwan bourse filing.The company did not provide comparative year-ago figures.Operating revenue accumulated stood at NT$208.3 million, the optical and electro-mechanical components manufacturer said.
$TPE:4977
Asia
CapitaLand Integrated Commercial Trust Issues 326.1 Million New Units
CapitaLand Integrated Commercial Trust (SGX:C38U) issued 326.1 million units at SG$2.30 per unit via a private placement, according to a Wednesday filing with the Singapore Exchange.Trading in the new units commenced on the same day, the filing added.
$SGX:C38U
Asia
Garden Reach Shipbuilders & Engineers Clocks Gains in Fiscal Q4 Profit; Shares Jump 11%
Garden Reach Shipbuilders & Engineers (NSE:GRSE, BOM:542011) recorded a rise in its profit to 3.03 billion Indian rupees in the fiscal fourth quarter against 2.44 billion rupees a year ago, according to a Tuesday filing to the Indian stock exchanges by the shipbuilder.Shares of the company jumped nearly 11% in recent trade.Earnings per share climbed to 26.47 rupees compared with a year-ago figure of 21.32 rupees.Revenue from operations in fiscal Q4 also increased to 21.2 billion rupees from 16.4 billion rupees a year earlier.The company's board also declared a final dividend of 6.70 rupees per share for the financial year 2025-26.
$BOM:542011$NSE:GRSE